Combination of aztreonam, ceftazidime-avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis

被引:16
|
作者
Mularoni, Alessandra [1 ]
Mezzatesta, Maria Lina [2 ]
Pilato, Michele [3 ]
Medaglia, Alice Annalisa [1 ,4 ]
Cervo, Adriana [1 ,5 ]
Bongiorno, Dafne [2 ]
Aprile, Ausilia [2 ]
Luca, Angelo [6 ]
Stefani, Stefania [2 ]
Grossi, Paolo [7 ]
机构
[1] ISMETT, IRCCS, Mediterranean Inst Transplantat & Adv Specialized, Dept Infect Dis & Infect Control, Palermo, Italy
[2] Univ Catania, Sect Microbiol, Dept Biomed & Biotechnol Sci, Catania, Italy
[3] ISMETT, IRCCS, Mediterranean Inst Transplantat & Adv Specialized, Dept Treatment & Study Cardiothorac Dis & Cardiot, Palermo, Italy
[4] Univ Palermo, Infect Dis Unit, Dept Hlth Promot Mother & Child Care, Internal Med & Med Specialties, Palermo, Italy
[5] Azienda Osped Univ Policlin Modena, Dept Infect Dis, Modena, Italy
[6] ISMETT, IRCCS, Mediterranean Inst Transplantat & Adv Specialized, Radiol Serv, Palermo, Italy
[7] Univ Insubria, Dept Med & Surg, Infect Dis Sect, Varese, Italy
关键词
Pseudomonas aeruginosa; ST235; VIM-1; Ceftazidime-avibactam; Aztreonam; Osteomyelitis; BETA-LACTAMASE;
D O I
10.1016/j.ijid.2021.05.085
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
We describe a challenging case of patient with metallo-beta-lactamase-producing Pseudomonas aeruginosa sternal osteomyelitis following aortic valve replacement with biological prosthesis. The strain exhibited a multidrug-resistance phenotype carrying the blaVIM-1 gene and belonged to the high-risk clone sequence type ST235. The patient was successfully treated with surgical debridement plus antibiotic therapy with ceftazidime/avibactam, aztreonam, and amikacin. Time-kill curves showed that this triple antibiotic combination at 1 x MIC was strongly synergic after 8 h, achieving 99.9% killing and maintaining this until 48 h. (c) 2021 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:510 / 512
页数:3
相关论文
共 50 条
  • [1] CEFTAZIDIME-AVIBACTAM AND AZTREONAM AGAINST MULTIDRUG- RESISTANT PSEUDOMONAS AERUGINOSA
    Toor, Rebecca
    Garcia, Esther
    CRITICAL CARE MEDICINE, 2020, 48
  • [2] In vitro activity of ceftazidime-avibactam/aztreonam combination against MBL-producing Pseudomonas aeruginosa strains
    Klein, Niklas
    Jantsch, Jonathan
    Simon, Michaela
    Roedel, Juergen
    Becker, Soeren L.
    Serr, Annerose
    Steinmann, Joerg
    Ehrentraut, Stefan F.
    Mollitor, Ernst
    Hischebeth, Gunnar T. R.
    INFECTION, 2024,
  • [3] Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa
    Daikos, George L.
    da Cunha, Clovis Arns
    Rossolini, Gian Maria
    Stone, Gregory G.
    Baillon-Plot, Nathalie
    Tawadrous, Margaret
    Irani, Paurus
    ANTIBIOTICS-BASEL, 2021, 10 (09):
  • [4] Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa
    Corbella, Laura
    Boan, Jorge
    San-Juan, Rafael
    Fernandez-Ruiz, Mario
    Carretero, Octavio
    Lora, David
    Hernandez-Jimenez, Pilar
    Ruiz-Ruigomez, Maria
    Rodriguez-Goncer, Isabel
    Tiago Silva, Jose
    Lopez-Medrano, Francisco
    Lizasoain, Manuel
    Villa, Jennifer
    Manuel Caro-Teller, Jose
    Aguado, Jose M.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 59 (02)
  • [5] Overexpression of blaGES-1 due to a strong promoter in the class 1 integron contributes to decreased ceftazidime-avibactam susceptibility in carbapenem-resistant Pseudomonas aeruginosa ST235
    Li, Xi
    Zhang, Xiaofan
    Cai, Heng
    Zhu, Yiwei
    Ji, Jingshu
    Qu, Tingting
    Tu, Yuexing
    Zhou, Hua
    Yu, Yunsong
    DRUG RESISTANCE UPDATES, 2023, 69
  • [6] Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa
    Lee, Michelle
    Abbey, Taylor
    Biagi, Mark
    Wenzler, Eric
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2021, 99 (01)
  • [7] Nosocomial dissemination of VIM-2-producing ST235 Pseudomonas aeruginosa in Lithuania
    Mikucionyte, G.
    Zamorano, L.
    Vitkauskiene, A.
    Lopez-Causape, C.
    Juan, C.
    Mulet, X.
    Oliver, A.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2016, 35 (02) : 195 - 200
  • [8] Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa
    Mikhail, Sandra
    Singh, Nivedita B.
    Kebriaei, Razieh
    Rice, Seth A.
    Stamper, Kyle C.
    Castanheira, Mariana
    Rybak, Michael J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (08)
  • [9] Nosocomial dissemination of VIM-2-producing ST235 Pseudomonas aeruginosa in Lithuania
    G. Mikucionyte
    L. Zamorano
    A. Vitkauskiene
    C. López-Causapé
    C. Juan
    X. Mulet
    A. Oliver
    European Journal of Clinical Microbiology & Infectious Diseases, 2016, 35 : 195 - 200
  • [10] Emergence of KPC-31, a KPC-3 Variant Associated with Ceftazidime-Avibactam Resistance, in an Extensively Drug-Resistant ST235 Pseudomonas aeruginosa Clinical Isolate
    Faccone, Diego
    de Mendieta, Juan M.
    Albornoz, Ezequiel
    Chavez, Magali
    Genero, Fabiana
    Echegorry, Mariano
    Ceriana, Paola
    Mora, Andrea
    Seah, Christine
    Corso, Alejandra
    Melano, Roberto G.
    Pasteran, Fernando
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (11)